Neogen Chemicals Ltd Q1 FY27 Earnings Analysis
Published 28 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹4.5K Cr
Price
₹1,777
Market Cap
₹4.5K Cr
P/E Ratio
169.0
Revenue Rank
Margin Rank
Earnings Summary
- FY27 standalone (non-battery) revenue guidance: INR 875 to 950 crore; aiming to achieve up to INR 1,000 crore with organolithium/lithium sales growth. - Revenue at Neogen is expected to grow significantly, targeting INR 3,700 to INR 4,200 crore consolidated revenue by FY29, including battery materials and existing business lines.
📊 Revenue & Sales Performance
Rank 2- FY27 standalone (non-battery) revenue guidance: INR 875 to 950 crore; aiming to achieve up to INR 1,000 crore with organolithium/lithium sales growth. - FY28 Neogen full utilization target: INR 1,100+ crore revenue from existing business with optimization. - FY29 revenue projections: - Neogen business: INR 1,200 to 1,400 crore, conservatively INR 1,200-1,250 crore. - Battery chemicals (Neogen Ionics): INR 2,500 to 2,900 crore. - Consolidated revenue expected: INR 3,700 to 4,200 crore, potentially higher with additional salt capacity investments. - Electrolyte and salt capacity at Pakhajan site can scale up to 3x current 30 GWh to meet future demand. - Brownfield expansions at organolithium, Dahej, and Baroda sites could support revenues of INR 4,000 to 5,000 crore over 5 years. - Long-term (FY31 and beyond) growth dependent on further CAPEX in electrolyte salt, CSM, semiconductor, organolithium, and inorganic lithium segments.
📈 Profitability & Margins
Rank 3- Revenue at Neogen is expected to grow significantly, targeting INR 3,700 to INR 4,200 crore consolidated revenue by FY29, including battery materials and existing business lines. - Neogen standalone business revenue is guided between INR 875 to INR 950 crore in FY27, with efforts to reach the higher end or INR 1,000 crore possible due to organolithium and lithium sales. - EBITDA margins are maintained around 17.8% despite expansion-related overheads, with improved operating leverage expected as facilities scale up. - ROCE is targeted at 18% to 20% for battery chemical projects, reflecting strong returns despite increased capital expenditure. - Profit after tax for Q4 FY26 stood at INR 11 crore, with annual PAT at INR 29 crore, signaling resilient profitability amid growth investments. - Expansion projects completion (Dahej, Pakhajan) and increased capacity will further support revenue and earnings growth beyond FY29.
🏗️ Capital Expenditure Plans
Yes- Additional investment expected in FY28 to increase salt capacity due to rising local and international electrolyte salt demand. - Potential further investments to expand organolithium, semiconductor-related, flavor & fragrance, and higher CSM needs. - Brownfield expansions planned at organolithium, Dahej, and Baroda sites targeting INR 4,000 to INR 5,000 crore revenue capacity. - Pakhajan facility capacity can be expanded up to 3x current 30 GWh electrolyte & salt capacity over five years depending on demand. - Revised project timeline for Pakhajan Phase 2 set for March 2027; includes electrolyte formulation and salted intermediate capacity. - Existing CAPEX funded through INR 160 crore equity from promoters plus $20 million from JV partner. - Peak debt level remains unchanged despite CAPEX increase. - Total gross block at Neogen Ionics expected to be around INR 1,700 to 1,800 crore by end FY27.
💰 Fundraising & Capital Structure
Yes- No additional funding is needed during FY27 for ongoing expansion projects. - INR 160 crore equity infusion from promoters and $20 million from JV partner Morita have been factored in. - These funds, along with an expected INR 200 crore insurance claim, are sufficient to complete projects and meet initial requirements. - Peak debt is expected to remain around the previously indicated INR 1,700 crore level; no increase anticipated. - One-year moratorium on principal repayments will apply from the start of commercial operations, providing cash flow relief. - Interest payments will begin immediately after commercial operations start; interest is capitalized during project phase.
📋 Order Book & Pipeline
YesThe transcript in the provided pages does not explicitly mention current or expected orderbook or pending orders in defined figures. However, relevant insights include: - Strong demand and capacity utilization expected in battery electrolyte and salt business. - Existing capacity at Pakhajan supports around 30 GWh of electrolyte and salt production with potential to triple capacity. - Additional investments anticipated in electrolyte salt capacity due to rising local and international demand. - Capacity expansions planned at organolithium, Dahej, and Baroda sites with potential revenue reach of INR 4,000-5,000 crore via brownfield expansions. - Positive discussions ongoing for 6 gigafactories under construction. - The company highlights ability to meet 100% of key customer's electrolyte demand (2,000 MT current capacity plus 30,000 MT by H1). - Demand visibility includes higher electrolyte usage with customers scaling up to 2.5 GW capacities. - Neogen targets consolidated revenue of INR 3,700-4,200 crore by FY29 based on current projections and orders. No specific orderbook or pending order numbers were disclosed.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Neogen Chemicals Ltd Q1 FY27 results?
- FY27 standalone (non-battery) revenue guidance: INR 875 to 950 crore; aiming to achieve up to INR 1,000 crore with organolithium/lithium sales growth. - Revenue at Neogen is expected to grow significantly, targeting INR 3,700 to INR 4,200 crore consolidated revenue by FY29, including battery materials and existing business lines.
What is Neogen Chemicals Ltd share price analysis?
Neogen Chemicals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 169.0 with a market cap of ₹4,484. Investors should review the full earnings analysis for detailed insights.
Is Neogen Chemicals Ltd planning capital expenditure?
- Additional investment expected in FY28 to increase salt capacity due to rising local and international electrolyte salt demand.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
